Drugs and FDA

FDA approves Livsayis as first siRNA therapy for myasthenia gravis

Livsayis is approved for adults with generalized myasthenia gravis who test positive for anti-AChR antibodies and is given by injection four times a year.

Reported by 4 outlets Friday, November 20, 2026

Pink tablets in a blister pack
Photo: CC0

The FDA approved Regeneron’s Livsayis, also called cemdisiran, for adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the company announced. It is the first approved small interfering RNA therapy for the condition and is given by subcutaneous injection four times a year.

Approval was based on the 24-week phase III NIMBLE trial. MedPage Today reported that MG-ADL scores improved from baseline by 4.5 points with cemdisiran and 2.2 points with placebo, an adjusted improvement of 2.3 points (P=0.0005). At 24 weeks, QMG scores improved by 4.2 points with the drug and 1.5 points with placebo, an adjusted improvement of 2.8 points (P=0.0015). MG-ADL improvements were seen as early as 2 weeks.

The drug carries a boxed warning for serious and life-threatening meningococcal infections and is available only through a risk evaluation and mitigation strategy program, Regeneron said. MedPage reported serious adverse events in 3% of the cemdisiran group and 14% of placebo participants.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.